Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.
The advent of anti-HER2 targeted therapies has dramatically improved the outcome of HER2-positive breast cancer; however, resistance to treatment in the metastatic setting remains a challenge, highlighting the need for novel therapies. The arrival of new treatment options and clinical trials examini...
| Publicado en: | Current Oncology Vol. 29; no. 4; pp. 2720 - 2735 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Apr2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156533372&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 156533372 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Apr2022 vid: 29 iid: 4 pid: 97109 pub: MDPI artinfo: ui: 156533372 10.3390/curroncol29040222 156533372 ppf: 2720 ppct: 15 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective. aug: au: Ferrario, Cristiano Christofides, Anna Joy, Anil Abraham Laing, Kara Gelmon, Karen Brezden-Masley, Christine affil: Department of Oncology, McGill University, Montreal, QC H3A OG4, Canada sug: ab: The advent of anti-HER2 targeted therapies has dramatically improved the outcome of HER2-positive breast cancer; however, resistance to treatment in the metastatic setting remains a challenge, highlighting the need for novel therapies. The arrival of new treatment options and clinical trials examining the efficacy of novel agents may improve outcomes in the metastatic setting, including in patients with brain metastases. In the first-line setting, we can potentially cure a selected number of patients treated with pertuzumab + trastuzumab + taxane. In the second-line setting, clinical trials show that trastuzumab deruxtecan (T-DXd) is a highly effective option, resulting in a shift from trastuzumab emtansine (T-DM1) as the previous standard of care. Moreover, we now have data for patients with brain metastases to show that tucatinib + trastuzumab + capecitabine can improve survival in this higher-risk group and be an effective regimen for all patients in the third-line setting. Finally, we have a number of effective anti-HER2 therapies that can be used in subsequent lines of therapy to improve patient outcomes. This review paper discusses the current treatment options and presents a practical treatment sequencing algorithm in the context of the Canadian landscape. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|